Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) shares rose 5.2% on Friday . The company traded as high as $91.45 and last traded at $88.11. Approximately 13,619,652 shares traded hands during mid-day trading, an increase of 2% from the average daily volume of 13,370,095 shares. The stock had previously closed at $83.75.
Analyst Ratings Changes
TEM has been the subject of several research analyst reports. Bank of America raised their price objective on Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Guggenheim began coverage on Tempus AI in a research note on Monday, December 9th. They set a "buy" rating and a $74.00 price target for the company. Loop Capital decreased their price objective on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a research report on Tuesday, January 14th. Piper Sandler restated a "neutral" rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, TD Cowen restated a "buy" rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $58.55.
View Our Latest Research Report on TEM
Tempus AI Stock Up 6.8 %
The business's fifty day moving average price is $46.60 and its 200 day moving average price is $50.37. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.
Insiders Place Their Bets
In other Tempus AI news, Director Jennifer A. Doudna sold 1,320 shares of Tempus AI stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $90.00, for a total value of $118,800.00. Following the completion of the sale, the director now owns 36,011 shares in the company, valued at $3,240,990. The trade was a 3.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Bradley A. Keywell sold 265,000 shares of the stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the transaction, the insider now owns 15,218,365 shares in the company, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 2,401,779 shares of company stock valued at $115,707,361.
Institutional Trading of Tempus AI
Several institutional investors have recently made changes to their positions in TEM. Clarus Group Inc. purchased a new stake in Tempus AI during the third quarter worth approximately $283,000. International Assets Investment Management LLC increased its holdings in Tempus AI by 141,400.0% in the 3rd quarter. International Assets Investment Management LLC now owns 70,750 shares of the company's stock valued at $4,004,000 after purchasing an additional 70,700 shares in the last quarter. Dakota Wealth Management purchased a new position in Tempus AI in the third quarter valued at about $1,185,000. Janney Capital Management LLC acquired a new position in shares of Tempus AI during the third quarter worth about $385,000. Finally, Vestor Capital LLC purchased a new stake in shares of Tempus AI in the third quarter worth about $153,000. 24.22% of the stock is owned by hedge funds and other institutional investors.
Tempus AI Company Profile
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Read More
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
